Karyopharm Therapeutics (KPTI) Current Leases (2019 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Current Leases came in at $969000.0 in Q4 2025, up 121.23% YoY from $438000.0 in Q4 2024, and up 5.1% on a QoQ basis from $922000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Current Leases (2019 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 7 years of Current Leases data on file, last reported at $969000.0 in Q4 2025.
- Quarterly Current Leases rose 121.23% year-over-year to $969000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $969000.0 (up 121.23% YoY) and the FY2025 annual result came in at $969000.0, up 121.23% from the prior year.
- Current Leases climbed to $969000.0 in Q4 2025, from $922000.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $3.7 million in Q3 2024 to a low of $438000.0 in Q4 2024.
- A 5-year average of $2.4 million and a median of $2.5 million in 2022 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2024 — Current Leases slumped 86.76% — and 2025, when it soared 121.23%.
- Tracing KPTI's Current Leases over 5 years: stood at $2.3 million in 2021, then grew by 24.01% to $2.9 million in 2022, then climbed by 15.18% to $3.3 million in 2023, then tumbled by 86.76% to $438000.0 in 2024, then surged by 121.23% to $969000.0 in 2025.
- The last three Current Leases figures came in at $969000.0 (Q4 2025), $922000.0 (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Karyopharm Therapeutics | 56.72 Mn | 56.72 Mn | 32.35 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.07 Mn |
| Dec 31, 2025 | 969,000.00 |
| Sep 30, 2025 | 922,000.00 |
| Jun 30, 2025 | 1.38 Mn |
| Mar 31, 2025 | 927,000.00 |
| Dec 31, 2024 | 438,000.00 |
| Sep 30, 2024 | 3.67 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | 3.31 Mn |
| Sep 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.08 Mn |
| Mar 31, 2023 | 2.98 Mn |
| Dec 31, 2022 | 2.87 Mn |
| Sep 30, 2022 | 2.77 Mn |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 2.46 Mn |
| Dec 31, 2021 | 2.32 Mn |
| Sep 30, 2021 | 2.16 Mn |
| Jun 30, 2021 | 2.08 Mn |